PubMed=8656685
Westendorf J.J., Ahmann G.J., Greipp P.R., Witzig T.E., Lust J.A., Jelinek D.F.
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Leukemia 10:866-876(1996)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=23992230; DOI=10.1111/ejh.12192; PMCID=PMC3834223
Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Eur. J. Haematol. 91:504-513(2013)

PubMed=24013424; DOI=10.4161/cc.26193; PMCID=PMC3865013
Walters D.K., Arendt B.K., Jelinek D.F.
CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.
Cell Cycle 12:3175-3183(2013)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017); University of Toronto; Toronto; Canada

PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300
Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B., Sirota M., Wiita A.P.
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Leukemia 34:2754-2765(2020)